News
OPK
1.490
-0.67%
-0.010
Weekly Report: what happened at OPK last week (0629-0703)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
OPKO Health (OPK) Ownership Update Draws Attention, Is The 55% Undervalued View Convincing?
Simply Wall St · 5d ago
Weekly Report: what happened at OPK last week (0622-0626)?
Weekly Report · 06/29 10:21
OPKO Health (OPK) Stock Could Be 57% Undervalued As Margin Recovery Comes Into Focus
Simply Wall St · 06/24 00:36
Weekly Report: what happened at OPK last week (0615-0619)?
Weekly Report · 06/22 10:31
Opko Health Shareholders Back Board, Equity and Auditors
TipRanks · 06/18 20:57
Opko Health shareholders approve 2026 equity incentive plan at annual meeting
PUBT · 06/18 20:07
OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update
Simply Wall St · 06/16 18:33
Entera Bio and Opko Health present preclinical data for oral peptides
TipRanks · 06/16 13:36
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
Benzinga · 06/16 12:44
Opko Health presents preclinical data for weekly acromegaly drug candidate OPK8801001 at ENDO 2026
PUBT · 06/15 12:01
Piper Sandler Sticks to Their Buy Rating for Opko Health (OPK)
TipRanks · 06/15 11:03
Weekly Report: what happened at OPK last week (0608-0612)?
Weekly Report · 06/15 10:32
Should OPKO’s New 15% Nicoya Stake and RAYALDEE Terms Require Action From OPKO Health (OPK) Investors?
Simply Wall St · 06/11 15:18
A Look At OPKO Health’s Valuation As Nicoya Agreement Expands RAYALDEE Opportunity In Asian Renal Care
Simply Wall St · 06/08 16:21
Weekly Report: what happened at OPK last week (0601-0605)?
Weekly Report · 06/08 10:27
OPKO Deepens Nicoya Alliance As RAYALDEE China Prospects Draw Focus
Simply Wall St · 06/06 02:27
Private Markets: Anthropic files confidentially for IPO with SEC
TipRanks · 06/04 15:16
Weekly Report: what happened at OPK last week (0525-0529)?
Weekly Report · 06/01 10:32
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.